Trial23 - A Method Study on Cervical Screening in Women Offered HPV-vaccination as Girls
Launched by UNIVERSITY OF COPENHAGEN · Feb 7, 2017
Trial Information
Current as of May 05, 2025
Active, not recruiting
Keywords
ClinConnect Summary
The Trial23 study is looking into how to best screen women for cervical health, particularly those who received the HPV vaccine as girls. The HPV vaccine helps protect against cervical cancer, and now that the first group of vaccinated women is reaching the age for cervical screenings, this trial aims to find a screening method that is easier and less burdensome for them.
To participate in this study, women born in 1994 and living in the area of the trial can take part. There are no specific exclusions, making it open to all eligible women. While the trial is currently active, it is not recruiting new participants at this time. If you’re part of this age group, you can expect to learn more about how cervical screening can be improved for those who have been vaccinated, which could help make the process smoother for everyone.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women born in 1994 living in the study area
- Exclusion Criteria:
- • None, as it is a public health trial
About University Of Copenhagen
The University of Copenhagen, a leading research institution in Denmark, is dedicated to advancing medical knowledge and improving patient outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its expertise in various fields, including health sciences, pharmacology, and biotechnology, to design and conduct rigorous clinical studies. Committed to ethical standards and scientific integrity, the University of Copenhagen aims to contribute significantly to the global medical community by facilitating groundbreaking research that addresses pressing healthcare challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Patients applied
Trial Officials
Elsebeth Lynge, Professor
Principal Investigator
University of Copenhagen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials